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Disease Activity and Bone Mass In Comparison with Chloroquine Treatment 
DIRKJAN VAN SCHAARDENBURG, ROELF VALKEMA, BEN A. C. DIJKMANS, 
SOCRATES PAPAPOULOS, AEILKO H. ZWINDERMAN, K. HUBERT HAN, 
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Objective. Prednisone is frequently used in the 
treatment of elderly-onset rheumatoid arthritis (RA), 
but the balance between efficacy and toxicity, including 
the effect on bone mass, has not been investigated in 
long-term studies. This prospective, randomized study 
was undertaken to compare disease activity and bone 
mass during long-term treatment with prednisone ver- 
sus chloroquine in this patient population. 
Methods. Patients with active RA diagnosed at 
age 260  were randomized to receive prednisone (15 
mg/day for 1 month, with the dosage tapered as low as 
possible thereafter) (n = 28) or chloroquine (n = 28). 
Patients who did not show a response received other 
second-line drugs as an adjunct to prednisone or as a 
replacement for chloroquine. Bone mass was measured 
by dual-energy x-ray absorptiometry. The study dura- 
tion was 2 years. 
Results. During the 2 years, treatment with other 
second-line drugs was needed for 12 patients in the 
prednisone group (43%) and 8 in the chloroquine group 
(29%). Functional capacity and disease activity im- 
proved significantly in both groups and did not differ 
significantly between the groups, except for a greater 
improvement in the prednisone group at 1 month. 
Radiographic scores for joint destruction progressed 
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similarly in both groups. There was a nonsignificant 
excess bone loss of 1.8% in the spine and 1.5% in the hip 
in the prednisone group, compared with the chloroquine 
group. 
Conclusion. Neither treatment was entirely satis- 
factory since a significant number of patients needed an 
additional second-line drug over the 2-year period. 
Since their introduction in 1949 ( I ) ,  the use of 
corticosteroids in the management of rheumatoid ar- 
thritis (RA) has remained controversial ( 2 4 ) .  In the 
initial long-term studies of cortisone, a greater reduc- 
tion of disease activity in the first 2 months was found 
compared with aspirin treatment, but later evaluations 
showed no differences between treatment groups in 
disease activity, functional capacity, or radiographic 
progression (5-7). Adverse events due to cortisone 
were substantial (6,7). Two other long-term studies 
demonstrated a greater reduction of disease activity 
(8) and fewer erosions (8-10) in patients treated with 
prednisolone compared with patients treated with an- 
algesic agents (8,9), or in patients treated with pred- 
nisone in combination with a disease-modifying anti- 
rheumatic drug (DMARD) compared with patients 
treated with only a DMARD (10). It has been reported 
that long-term low-dose prednisone (usually at < 10 
mg/day) has been used in the treatment of approxi- 
mately one-third of RA patients seen in clinical prac- 
tice (11,12). Open studies have shown good results 
with prednisone as the only second-line drug, in par- 
ticular for patients with elderly-onset RA (13,14). 
A major drawback with the use of prednisone is 
osteoporosis. Cross-sectional studies have shown that 
RA patients tend to have lower bone mass compared 
with controls, which has mainly been attributed to 
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physical inactivity and corticosteroid use (15,16). An 
increased risk of fractures in RA patients has been 
observed in association with prednisone treatment at 
>5 mg/day (17-20). However, no long-term random- 
ized trials of prednisone for RA that included measure- 
ments of bone mass have thus far been reported. The 
purpose of the present study was to compare the 
efficacy and toxicity of long-term low-dose prednisone 
versus chloroquine as the initial second-line treatment 
in active elderly-onset RA. Loss of bone mass was the 
feature that was focused on with respect to toxicity. 
PATIENTS AND METHODS 
Patients. Inclusion criteria were as follows: a diagno- 
sis of definite or classic RA according to the 1958 criteria of 
the American College of Rheumatology (formerly, the Amer- 
ican Rheumatism Association) (21) at the age of 60 years or 
over, and active disease that was unresponsive to 3 months 
of nonsteroidal antiinflammatory drug (NSAID) therapy. 
Active disease was defined as the presence of 2 3  swollen 
joints and at least 2 of the following: a modified Ritchie 
articular index (RAI) (22) of 29 ,  morning stiffness of 245 
minutes, and an erythrocyte sedimentation rate (ESR) of 
228 mdhour .  Exclusion criteria were the use of a DMARD 
or prednisone during the preceding 3 months, the use of 
thiazide diuretics, inadequately controlled hypertension, ac- 
tive peptic ulcer disease, diabetes mellitus, hepatic disease, 
renal disease, ophthalmologic contraindications to chloro- 
quine treatment, osteoporosis with vertebral fracture or 
biconcave deformity as judged on lateral radiographs of the 
thoracic and lumbar spine, and other serious diseases that 
would preclude the evaluation of therapeutic effects. 
The protocol was approved by the Ethics Committee 
of Leiden University Hospital. Oral informed consent was 
obtained. Patients were recruited in 1990 and 1991 from 
Leiden University Hospital and the Daniel den Hoed Clinic. 
Randomization was performed within each center, using 
numbered envelopes. Fifty-six RA patients were enrolled in 
the study: 49 from Leiden University Hospital and 7 from 
the Daniel den Hoed Clinic. 
Treatment. Patients received either chloroquine (n = 
28) or prednisone (n = 28). The chloroquine dosage was 100 
mglday after a loading phase of 100 mg 3 times daily during 
the first month and 100 mg twice daily during the second 
month. In the event of dose-dependent adverse effects, the 
highest tolerated dosage in the above schedule was used, but 
not less than 100 mg per day. In the event of lack of efficacy 
after at least 3 months of treatment, chloroquine was re- 
placed by intramuscular gold (aurothioglucose in oil, 50 
mglweek). If chloroquine was discontinued because of ad- 
verse events and the disease was active, gold treatment was 
started. After a failure or side effect of gold, sulfasalazine 
(2,000 mglday) was the next drug to be used. The use of 
prednisone was not allowed among patients in the chloro- 
quine group. 
Prednisone was given in a dosage of 15 mglday as a 
single morning dose for 1 month. If there was clinical 
improvement in the opinion of the patient after 1 month, the 
dosage was decreased by 2.5 mglday at intervals of 4 weeks 
until the lowest possible dosage was reached where the 
clinical improvement was maintained. If the patient then 
reported increasing disease activity, the dosage was in- 
creased in the same stepwise manner to a maximum level of 
15 mglday. A failure of prednisone was defined as the 
absence of clinical improvement in the opinion of the patient 
3 months after the start of treatment or, at a later stage, the 
need for a dosage of 15 mglday for more than 1 month. In 
either of these events, chloroquine was added to the regimen 
in the same dosage as used for the other treatment group, 
and the prednisone dosage was adjusted as described above. 
Chloroquine was also prescribed when prednisone had to be 
decreased or discontinued because of adverse events and the 
disease activity criteria were fulfilled. The patients were 
seen monthly during the first 3 months and at intervals of 1-3 
months thereafter. 
All patients were treated with a stable dosage of 
NSAID, 500 mg of an oral calcium preparation in the 
evening, and, if the serum level of 25-hydroxyvitamin D was 
<30 nmoles/liter prior to treatment, 400 units/day of chole- 
calciferol. Prednisone-treated patients with a history of 
tuberculosis were prescribed isoniazid 300 mgiday. 
Clinical assessment. The clinical assessments were 
performed by a research nurse who was blinded to the 
treatment. The following parameters were measured at 0, 1, 
3, 12, and 24 months: patient assessment of disease in 
comparison with baseline (4-point scale: worse, equal, slight 
improvement, or marked improvement), the Dutch Health 
Assessment Questionnaire (HAQ) (23), which is a translated 
and validated version of the original questionnaire (24), 
number of swollen joints (counting metacarpophalangeal, 
proximal interphalangeal, or metatarsophalangeal joints on 1 
side as 1 joint; maximum 20), a modified RAI (maximum 
value 69), and ESR. The presence of adverse advents was 
documented by the treating physician. 
Radiographs of the wrists, hands, and forefeet at 0, 
12, and 24 months were assessed according to the criteria of 
Kellgren (25), by 2 rheumatologists who reviewed the radio- 
graphs together and were blinded to the treatment group. 
Erosions and joint space narrowing were each scored on a 
5-point scale (0 = no abnormalities, 1 = doubtful abnormal- 
ities, 2 = mild but definite abnormalities, 3 = moderate 
erosions or joint space narrowing, and 4 = severe destruc- 
tive lesions andor ankylosis, or total loss of joint space). 
The total number of affected joints was defined as the 
number of joints having erosions and/or joint space narrow- 
ing (score 22). The maximum possible number of affected 
joints was 50, resulting in a maximum possible radiologic 
score of 200. 
Effects on bone. Patients with concurrent illnesses 
that might affect bone mass were not included in this 
evaluation. The following factors with possible influence on 
bone mass measurements were determined at entry: body 
mass index (BMI; kg/m2), degree of osteophytosis in the 
lumbar spine (26), and physical activity (27). Physical activ- 
ity was also scored at the end of the study, and the mean 
value was used for analysis. 
Bone mass measurements were made at 0 ,6 ,  12, and 
24 months by dual-energy x-ray absorptiometry (DXA) 
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(QDR 1000; Hologic, Waltham, MA). The short-term preci- 
sion error in bone mineral density (BMD) during daily spine 
phantom measurements was 0.40%, while no significant time 
trend was observed (mean ? SD -0.02 * 0.07% per year). 
The short-term precision error for hip BMD using a hip 
phantom was 3.0%. 
The lumbar spine (LkL4) was measured twice with 
repositioning of the patient between measurements; the 
mean value of the bone mineral content (BMC) was used for 
analysis. In our opinion, BMC is preferable to BMD for the 
longitudinal evaluation of spinal bone mass (28). Duplicate 
measurements at the start of the study in the RA patients 
demonstrated a short-term precision error in BMC of 1.9% 
(29). For the femoral neck, the mean value of the left and 
right BMD was used for analysis. In patients who had had a 
unilateral arthroplasty (1 in each treatment group), the value 
of 1 side only was used. The BMD values of spine and hip 
were compared with the mean values for age- and sex- 
matched controls from a database supplied by the manufac- 
turer of the densitometer, expressed as standard deviation (Z 
score). 
A control group of 21 age- and sex-matched patients 
(8 male, 13 female; mean age 65 years, range 60-79) with 
miscellaneous noninflammatory conditions, recruited from 
the rheumatology outpatient clinic, was also studied after 
informed consent was obtained. The female patients in all 3 
groups had been postmenopausal for more than 5 years. 
The following biochemical parameters of bone me- 
tabolism were measured in RA and control patients at the 
start of the study and in RA patients also at 6,  12, and 24 
months: serum alkaline phosphatase, osteocalcin (by radio- 
immunoassay) (30), and parathyroid hormone (PTH) (by 
immunoradiometric assay; Incstar, Stillwater, MN) (31), and 
creatinine, calcium, and hydroxyproline (32) in a 2-hour 
morning urine sample (second void). Alkaline phosphatase, 
creatinine, and calcium were measured by standard auto- 
mated laboratory methods. After the evening meal of the 
preceding day, only water and medication, excluding the 
calcium tablet, were allowed. 
Statistical analysis. The two main study questions 
were whether a regimen starting with prednisone as the 
initial second-line drug was as effective as a regimen starting 
with chloroquine, and whether bone loss was higher during 
treatment with prednisone compared with chloroquine. 
Based on previous studies with chloroquine in early RA, an 
improvement of at least 40% in the swollen joint count in the 
chloroquine group was expected (33). With an a level of 5% 
and a p level of lo%, a sample size of 22 patients per study 
arm is necessary to detect a between-group difference in 
Table 2. Radiographic scores at study entry 
treated with prednisone or chloroquine* 
Table 1. 
arthritis patients treated with prednisone or chloroquine 
General characteristics at study entry, in rheumatoid 
Prednisone Chloroquine 
group group 
Variable (n = 28) (n = 28) 
Age in years, mean (range) 69 (60-77) 70 (60-84) 
% females 71 43 
Disease duration in months, 11 (3-106) 10 (3-120) 
% with elevated IgM rheumatoid 86 63 
mean (range) 
factor titer 
improvement of at least 4 joints for the swollen joint count. 
Based on earlier longitudinal studies of prednisone in RA, a 
4% variance of bone mass loss in the spine was assumed 
(34). With a = 5% and p = 20%, 20 patients per study arm 
is the sample size necessary to detect a difference of 1.4% in 
bone mass loss between groups. 
The analysis was based on the intention-to-treat 
principle. Comparisons of outcome parameters were made 
within the groups and between the groups with repeated- 
measures (mixed-model) analysis of variance. In this man- 
ner, the available data on patients not completing the study 
are included in the analysis. Comparisons at single time 
points were made with Student's t-test or the Mann-Whitney 
U test, as appropriate. The relation of several factors to bone 
mass loss was tested with Pearson's product-moment corre- 
lation and multiple regression analysis. 
RESULTS 
Outcome. At study entry, the 2 groups were 
comparable with regard to demographic and clinical 
characteristics (Tables 1 and 2 and Figure l), except 
for a higher proportion of females and a higher per- 
centage of patients with an elevated serum IgM rheu- 
matoid factor titer in the prednisone group. Most 
patients were in an early stage of the disease: 91% 
were enrolled in the study less than 18 months after 
RA was diagnosed. None of the patients had previ- 
ously been treated with oral corticosteroids. Two 
patients in each group had been previously treated 
with 1 DMARD. 
and at 24 months, in rheumatoid arthritis patients 
Prednisone group Chloroquine group 
Entry 24 months Entry 24 months 
Joint space narrowing score 6.8 L 6.9 6.8 2 8.2 8.0 * 8.9 5.4 2 9.3 
Erosion score 4.8 L 6.5 5.1 * 5.4 4.6 * 7.3 5.5 2 8.0 
2.5 2 4.8 No. of affected ioints 2.8 2 3.3 3.3 2 3.3 3.7 2 4.7 
* Values are the mean * SD. 
PREDNISONE VS. CHLOROQUINE IN RA 
2.00 
(a) HAQ ,,,I ] 
337 
(3 Ritehie score 20. 
18 - 
T 
75 
(b) ESR 
65 ~ 
0 
(d) Swollen joint count 10 - 
8. 
6 .  I 
4 .  I 
7 
Four patients died during the study, all in the 
chloroquine group. The causes of death were rheuma- 
toid pericarditis, pneumonia, lung cancer, and gastric 
cancer, and were considered not to be related to the 
chloroquine treatment. 
A similar percentage of patients in both groups 
completed 2 years of treatment with the drug to which 
they were originally assigned. In the prednisone 
group, 12 patients (43%) prematurely discontinued 
prednisone as single therapy, 9 because of failure and 
3 because of adverse events, i.e., cushingoid features 
in all 3. Three patients who discontinued prednisone as 
single therapy later switched from chloroquine to gold 
treatment, and 1 subsequently switched to sulfasala- 
zine treatment. The mean daily dosage of prednisone 
was 11.4 mg (range 7.9-13.8 mg) over the first 6 months, 
8.2 mg (range 3.3-13.8 mg) over the second 6 months, 6.3 
mg (range 0-11.7 mg) over the second year, and 8 mg 
(range 3.3-11.9 mg) over the whole 2-year period. 
After 2 years, 24 patients were still taking prednisone. 
The mean daily dosage at 2 years in patients still taking 
prednisone was 7.1 mg (range 2.5-10 mg). 
In the chloroquine group, 11 patients (39%) 
prematurely discontinued the study treatment. The 
reasons were lack of efficacy in 4 patients, adverse 
events in 5 ,  and death in 2 (the other 2 patients who 
died had already discontinued chloroquine, because of 
lack of efficacy in 1 and an adverse event in the other). 
The adverse events that led to chloroquine discontin- 
uation were nausea and/or rash. Eight patients started 
gold treatment after discontinuation of chloroquine, of 
whom 3 were later treated with sulfasalazine. The first 
3 patients who were started on the chloroquine regi- 
men could not tolerate the 300-mg/day loading dose. 
Thus, for subsequent patients, the loading phase of 
chloroquine was changed to 100 mg once daily in the 
first week and 100 mg twice daily in the second week. 
Thereafter, the original schedule was followed. Of all 
patients randomized to receive chloroquine, 10 (36%) 
could not tolerate the full loading dose. Over the 2 
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years, DMARDs (including prednisone) were pre- 
scribed 43 times for patients in the prednisone group 
and 39 times for patients in the chloroquine group. 
Marked improvement relative to baseline was 
reported by 90% of the patients in the prednisone 
group at 1 month, but this decreased to 4641% at 3, 
12, and 24 months. In the chloroquine group, marked 
improvement was reported by 5042% of the patients 
at each time point after baseline. The changes over 
time in the HAQ and the disease activity parameters 
are shown in Figure 1 .  Within the groups, there was a 
significant improvement of all 4 parameters between 
baseline and 24 months (P < 0.01). An improvement of 
at least 30% in both the RAI and the swollen joint 
count between 0 and 24 months was found in 50% of 
the patients in the prednisone group and 46% of those 
in the chloroquine group. The course of the para- 
meters over time was not significantly different be- 
tween the groups, except for the ESR (P < 0.01). At 
individual time points, the only significant differences 
between groups were a lower swollen joint count and 
lower ESR in the prednisone group versus the chloro- 
quine group at 1 month (P < 0.01). 
The radiographic scores at entry and the 
changes between baseline and 24 months are shown in 
Table 2. The baseline scores did not differ significantly 
between the groups. There was a significant progres- 
sion within both groups (P < 0.01). The rate of 
progression was similar in the first and second year for 
both groups (data not shown). The number of affected 
joints increased between baseline and 24 months in 
84% of the patients in the prednisone group and 79% of 
the patients in the chloroquine group. The differences 
between the groups in the changes over the 2 years 
were not statistically significant. 
Bone mass. Complete bone mass measurements 
were obtained in 27 patients in the prednisone group 
(96%), 20 patients in the chloroquine group (71%), and 
21 patients in the control group (100%). The reasons 
for not measuring bone mass were primary hyperpar- 
athyroidism in 1 patient in the prednisone group, and 
death (n = 4), refusal (n = 2), testicular atrophy after 
orchitis (n = l) ,  and treatment with anti-androgens for 
carcinoma of the prostate (n = 1) in the chloroquine 
group. Femoral neck BMD could not be measured in 1 
prednisone-treated patient because of bilateral arthro- 
plasty; therefore, hip BMD was measured in 26 pa- 
tients in this group. Vitamin D supplements were given 
to 7 patients in the prednisone group, 9 in the chloro- 
quine group, and 4 in the control group. The frequency 
of definite osteophytes in the lumbar spine (score of 
Spine BMC 
1 
104 - 
94 - 
93 _- 
0 6 12 
months 
24 
Mean hip BMD 
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Figure 2. Spine bone mineral content (BMC) and hip bone mineral 
density (BMD) at various time points from baseline to 24 months, in 
rheumatoid arthritis patients treated with prednisone (0) or with 
chloroquine (0) and in control patients (0). Values are the mean f 
2 SEM percentage relative to baseline. 
22)  was 59% in the prednisone group, 60% in the 
chloroquine group, and 88% in the control group. Z 
scores were between -0.5 and 0.5 in the prednisone 
and chloroquine groups and -1  in the control group. 
The course of spine BMC and hip BMD over 
time is depicted in Figure 2. In the control group there 
was a 2.3% increase in mean spine BMC (95% confi- 
dence interval [95% CI] 0.4-4.1%) and a 0.7% de- 
crease in mean hip BMD (95% CI - 1-2.5%) over the 2 
years. In the chloroquine group there was a 1.8% 
decrease in spine BMC (95% CI - 1 4 . 5 % )  and a 4.8% 
decrease in hip BMD (95% CI 2.5-7.1%) over the 2 
years. The difference in the course of bone mass 
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Table 3. 
RA patients treated with chloroquine, and control patients* 
Bone metabolism parameters in rheumatoid arthritis (RA) patients treated with prednisone, 
Month 
Group, parameter 0 6 12 24 
~~ 
Prednisone (n = 27) 
ALP 
Osteocalcin 
PTH 
CdCr 
HOP/Cr 
ALP 
Osteocalcin 
PTH 
CdCr 
HOP/Cr 
Control (n = 21) 
ALP 
Osteocalcin 
PTH 
CdCr 
HOP/Cr 
Chloroquine (n = 20) 
58 t 25 
3.7 t 1.8 
1.7 t 1.3$ 
0.51 2 0.39 
31 t 16$ 
66 f 15$ 
3.8 f 1.1 
2.0 f 1.9 
0.39 2 0.25 
29 f 9$ 
46 2 10 
3.2 f 1.5 
3.2 t 2.0 
0.34 2 0.20 
17 2 5 
39 f I l t  
2.8 f 1.37 
2.2 2 1.2 
0.50 t 0.32 
22 f 171 
61 t 17 
3.6 2 1.7 
2.9 f 2.2t 
0.26 t 0.16 
25 f I1 
42 t 1s t  
2.3 f I.Ot 
2.5 f 2 . l t  
0.48 t 0.20 
18 t 17t 
61 f 15 
4.5 5 2.3 
0.45 t 0.45 
27 t 8 
3.7 2 1.8t 
49 t 17t 
2.5 t 0.97 
2.6 t I . l t  
0.47 f 0.28 
18 f 10t 
63 f 15 
3.8 2 2.0 
3.8 f 4.2 
0.29 t 0.18 
25 f 11 
* Values are the mean 5 SD. ALP = alkaline phosphatase; F'TH = parathyroid hormone; Ca/Cr = 
urinary calcium/creatinine ratio; HOP/Cr = urinary hydroxyproline/creatinine ratio. 
t P < 0.01 versus baseline. 
$ P < 0.01 versus controls. 
between the control group and the chloroquine group 
was significant both for the spine and for the hip ( P  < 
0.01 and P < 0.05, respectively). In the prednisone 
group there was a 3.6% decrease in spine BMC (95% 
CI 1.1-6.2%) and a 6.3% decrease in hip BMD (95% CI 
4.2-8.4%) over the 2 years. Nearly all the loss of spine 
BMC in this group occurred within the first 6 months, 
whereas the rate of BMD decrease in the hip was 
constant over time. In the second year the rates of 
bone loss at both sites were similar in both RA groups 
(Figure 2). The loss of spine BMC and hip BMD at 24 
months was 1.8% greater and 1.5% greater in the 
prednisone group than in the chloroquine group. The 
course of the bone mass was not significantly different 
between these 2 groups of RA patients. 
Bone metabolism. The biochemical parameters 
of bone turnover were measured in the same patients 
from whom bone mass measurements were obtained. 
At entry, the values in the prednisone group and the 
chloroquine group were similar (Table 3 ) .  Bone turn- 
over was higher in RA patients than in control pa- 
tients, as suggested by a higher alkaline phosphatase 
level in serum and a higher urinary hydroxyproline/ 
creatinine ratio (HOPICr). During followup, the serum 
alkaline phosphatase and osteocalcin levels decreased 
significantly in the prednisone group but not in the 
chloroquine group. Serum PTH increased significantly 
in both groups. The urinary calcium/creatinine ratio 
(CalCr) remained unchanged in both groups, as did the 
HOP/Cr ratio in the chloroquine group. HOP/Cr de- 
creased significantly in the prednisone group. 
Features possibly related to bone mass loss. 
Univariate correlations of the rates of bone mass loss 
over 2 years with sex, BMI, disease duration, osteo- 
phyte score, Z score, physical activity score, mean 
HAQ score, mean RAI, mean swollen joint count, 
baseline CdCr, and HOP/Cr, and (in the prednisone 
group) the mean prednisone dose over 2 years were 
tested. Significant (P < 0.01) correlations between the 
various factors and bone loss in the spine were not 
found. The highest correlation was with the mean 
prednisone dose (r = 0.41, P = 0.03). For bone loss in 
the hip, significant correlations with the mean HAQ 
score (r = 0.51), the mean physical activity score (r = 
-0.37), the mean swollen joint count (r = 0.41), and 
the mean prednisone dose (r = 0.60) were found. The 
rates of bone loss in the 2 treatment groups were then 
compared in a multiple regression model, correcting 
for the differences between the groups in sex distribu- 
tion, Z score, osteophyte score, physical activity, 
mean swollen joint count, and baseline CdCr and 
HOP/Cr. The differences in rates of bone mass loss in 
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the spine and hip between the 2 groups remained 
similar in the multiple regression model. An indepen- 
dent relationship with bone mass loss in the spine was 
found for the swollen joint count, and with bone mass 
loss in the hip for the swollen joint count and physical 
inactivity. 
Fractures. Four symptomatic fractures oc- 
curred in 4 patients (all women). In the first year, 1 
patient in the chloroquine group had a hip fracture. In 
the second year, 2 prednisone-treated patients had a 
thoracic vertebral crush fracture and 1 prednisone- 
treated patient fractured an elbow. The patients with 
fractures had Z scores between -0.5 and 0.5, and their 
values for bone turnover parameters at baseline were 
in the same range as those for patients without fractures. 
DISCUSSION 
This study compares the efficacy of prednisone 
and chloroquine as the initial treatment of RA in 
dosages that are widely used in clinical practice. The 
main conclusion is that the antiarthritic effect and the 
progression of radiographic signs of joint destruction 
are similar in both groups. The patients treated with 
prednisone had a greater loss of bone mass in the spine 
and the hip after 2 years, although the differences were 
not statistically significant. 
A clinical advantage of prednisone over chloro- 
quine was lower disease activity at 1 month in the 
patients treated with prednisone. During the remaining 
period of the study, however, the parameters of dis- 
ease activity did not differ significantly between the 
patient groups, which was reflected by the fact that 
similar numbers of patients were considered to need 
another DMARD. Although the sample size may not 
have been large enough to demonstrate a small differ- 
ence between the treatment groups, it is unlikely that 
even a much larger study would demonstrate a clini- 
cally significant difference. 
These results indicate that in the long-term 
treatment of active elderly-onset RA, a regimen start- 
ing with low-dose prednisone followed by chloro- 
quine, gold, and sulfasalazine has no more antiinflam- 
matory properties than a regimen starting with 
chloroquine. Changes in functional capacity, as well as 
the progression of radiologic abnormalities, were the 
same in both groups. Modification of radiologic pro- 
gression of joint destruction in RA during chloroquine 
therapy was not found previously (39 ,  and it can be 
concluded that prednisone also lacks such an effect. 
This result is in contrast with the findings of earlier 
studies on corticosteroids in the treatment of RA, which 
showed either no (8,9) or decreased (10) radiographic 
progression. It should be noted that in these earlier 
studies slightly higher prednisone dosages were used. 
Concerning the dosage of chloroquine, it is of 
interest that many patients did not tolerate a dosage of 
> 100 mg/day. It is also notable that 4 deaths occurred 
during chloroquine treatment, although there was no 
obvious relationship between the treatment and the 
deaths. In this clinical trial setting, chloroquine re- 
sulted in an unsatisfactory response in 29% of patients, 
whereas in clinical practice the likelihood of discon- 
tinuing antimalarial drugs after 2 years is 50% or more 
(12,36). It appears that regimens including other ther- 
apies in addition to chloroquine or prednisone are 
required for optimal control of RA in most patients. 
The relatively small differences in bone mass 
loss between the groups did not reach statistical sig- 
nificance. This may be explained by the relatively 
small number of patients studied, the higher variance 
in the amount of bone loss than was previously found 
(34), and the relatively low mean dosage of pred- 
nisone. However, the well-described association of 
prednisone therapy with osteoporosis (16), and the 
fact that a higher bone mass loss in both the spine and 
the hip relative to baseline was found at all time points 
in the prednisone group compared with the chloro- 
quine group, suggest that the loss of bone mass was 
indeed higher in the patients treated with prednisone. 
The loss of bone mass in the spine in the patients 
treated with prednisone occurred mainly within the 
first 6 months of treatment, as has been found previ- 
ously (34,37-39). In the present study a dose effect 
cannot be excluded, since the prednisone dosage was 
higher in the first half-year of treatment than in later 
periods. It is not likely that the difference in bone mass 
loss between the groups would have become signifi- 
cant if the study had lasted longer, since the loss 
during the second year was equal in both groups. 
The loss of trabecular bone in the vertebrae of 
RA patients may in reality be greater than was actually 
found, since BMC measurements by DXA can be 
influenced by growing osteophytes, as evidenced by 
an increase in BMC over time in the control group with 
a high frequency of osteoarthritis of the spine. In a 
study using quantitative computed tomography, which 
measures the trabecular BMD inside the vertebrae, an 
8.2% decline of BMD was found after 20 weeks of 
treatment with prednisone at a mean dosage of 7.5 
mg/day (39). 
The biochemical data show a sustained de- 
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crease of bone formation, a parallel decrease of bone 
resorption, and an increased serum PTH level in the 
patients treated with prednisone. The rates of bone 
mass loss in this group suggest that bone formation is 
relatively more depressed than bone resorption. Other 
prospective studies of bone metabolism during pred- 
nisone therapy have also demonstrated depressed 
bone formation (40-42), but results of bone resorption 
parameters and of serum PTH levels were variable 
(37,4042). The decrease in bone resorption may in 
part be juxtaarticular (43). The only change over time 
in the parameters of bone metabolism in the chloro- 
quine group was an increase in serum PTH, which may 
be a consequence of impaired calcium absorption due 
to chloroquine (44,45). A negative calcium balance 
induced by chloroquine may have attenuated the dif- 
ferences in bone loss between the groups. 
Three fractures occurred in the prednisone 
group and 1 in the chloroquine group. As expected in 
these small patient groups, the difference was not 
significant. The patients with fractures were all female, 
but they did not differ from the patients without 
fractures with respect to other risk factors measured. 
Bone mass loss in this study was related to physical 
inactivity, disease activity, and prednisone dose. Al- 
though the differences in bone mass loss between the 
groups were small, they should not be ignored, since 
even a small decrease in bone density is associated 
with an increased risk for fractures (46). 
An alternative design for the present study 
could have been to compare combined prednisone and 
chloroquine with chloroquine alone. In an attempt to 
reproduce the results of earlier studies, which contain 
evidence for an effect of prednisone on radiographic 
progression (2,4,8,9), we chose to study the effect of 
prednisone in sufficiently high doses as the only initial 
second-line drug. Prednisone was more efficacious 
than chloroquine in the treatment of elderly-onset RA 
in the first month, when the highest doses were used. 
The long-term effects of both drugs on disease activity, 
functional capacity, and radiographic progression 
were similar. The results of the present study suggest 
that long-term prednisone therapy leads to a higher 
loss of bone mass. It has been shown that the bone 
mass loss induced by a short period of prednisone 
therapy is reversible (39). Therefore there are argu- 
ments to support the use of prednisone in the initial 
treatment of active RA, alone or in combination with 
other drugs, and to minimize its use in long-term 
treatment. 
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